Incidence of Antiseizure Medication–Induced Severe Cutaneous Adverse Reactions in Malaysia

Antiseizure medication can potentially cause severe cutaneous adverse reactions, and certain antiseizure medication‐induced severe cutaneous adverse reactions are associated with specific human leukocyte antigen alleles. This caused a change in antiseizure medication prescribing patterns, which may influence the incidence of antiseizure medication‐induced severe cutaneous adverse reactions. Thus, we aimed to determine the incidence of antiseizure medication‐induced severe cutaneous adverse reactions and its change over 15 years (2006‐2019) in Malaysia. This retrospective analysis combined antiseizure medication‐induced SCAR cases from the national adverse drug reaction database in the National Pharmaceutical Regulatory Agency, antiseizure medication usage data from the Malaysian Statistics of Medicine, and prescribing data from University Malaya Medical Centre, a national‐level tertiary hospital to calculate antiseizure medication‐induced SCAR incidence in Malaysia. We observed an upward trend in reported antiseizure medication‐induced SCAR cases from 28 cases in 2006 to 92 in 2016. The incidence of carbamazepine (CBZ)‐induced severe cutaneous adverse reactions increased from 7.5 per 1000 person‐years (2006) to 17.8 per 1000 person‐years (2016) but dropped to 7.2 per 1000 person‐years subsequently (2019). Concurrently, there was an increase in the incidence of severe cutaneous adverse reactions secondary to phenytoin and lamotrigine. The prevalent users of CBZ had reduced from 22.8% (2006) to 14.1% (2016), whereas the levetiracetam and sodium valproate users increased by 5.5% and 4.8%, respectively. The incidence of CBZ‐induced severe cutaneous adverse reactions had reduced since 2016, probably related to the implementation of human leukocyte antigen‐B*1502 screening in Malaysia or substitution of CBZ with other antiseizure medications. However, this was accompanied by an increase in SCAR incidence related to phenytoin and lamotrigine.

[1]  B. Medhi,et al.  Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase® , 2021, Seizure.

[2]  Heung-Woo Park,et al.  Incidence rates of severe cutaneous adverse reactions due to antiseizure medication: A nationwide study using health claims data in Korea , 2020, Epilepsia.

[3]  R. Mani,et al.  Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature , 2019, Seizure.

[4]  N. Mehra,et al.  Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population , 2019, Seizure.

[5]  Si-qi Ding,et al.  Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015 , 2019, BMC Pharmacology and Toxicology.

[6]  S. Rüegg,et al.  The risk of Stevens‐Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs , 2017, Epilepsia.

[7]  C. Ng,et al.  HLA-A*31: 01 and HLA-B*15:02 association with Stevens–Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population , 2017, Pharmacogenetics and genomics.

[8]  A. Bircher,et al.  The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. , 2017, The Journal of investigative dermatology.

[9]  C. Ng,et al.  HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions , 2017, Neurology.

[10]  C. Ng,et al.  Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population , 2016, The Pharmacogenomics Journal.

[11]  J. Silverberg,et al.  Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. , 2016, The Journal of investigative dermatology.

[12]  H. Park,et al.  HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs , 2015, Yonsei medical journal.

[13]  C. Ng,et al.  Cross-reactivity in AED-Induced Severe Cutaneous Adverse Reaction: A Case Report. , 2016, Journal of investigational allergology & clinical immunology.

[14]  B. Lv,et al.  Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999–2014 , 2015, Journal of Clinical Neuroscience.

[15]  P. Kwan,et al.  Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions , 2014, Neurology.

[16]  C. Ng,et al.  HLA‐B*15:02 association with carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled‐data analysis and meta‐analysis , 2014, Epilepsia.

[17]  J. Wang,et al.  HLA-B*1502 Increases the Risk of Phenytoin or Lamotrigine Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Evidence from a Meta-analysis of Nine Case-control Studies , 2014, Drug Research.

[18]  P. Kwan,et al.  HLA‐B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese , 2013, Epilepsia.

[19]  E. Finkelstein,et al.  Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore , 2012, Neurology.

[20]  W. Chung,et al.  Severe cutaneous adverse reactions to antiepileptic drugs in Asians , 2011, Neurology.

[21]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[22]  M. Mockenhaupt,et al.  Severe Cutaneous Adverse Reactions to Drugs (SCAR): Definitions, Diagnostic Criteria, Genetic Predisposition , 2009 .

[23]  P. Kwan,et al.  Association of HLA-B*1502 allele and carbamazepine- induced severe adverse cutaneous drug reaction among Asians, a review , 2008 .